Blog
35 Articles
Decoding the Differences between At-Home and Medical Genetic Testing
Genetic counselors Jill Stopfer and Heather Hampel explain the differences between at-home and medical genetic testing, including precision and knowledge.
Clinical Trial For OncoTreat Being Developed
Researcher Kenneth Olive is developing OncoTreat, a method matches a patient’s tumor to the most effective drugs for their pancreatic cancer.
Looking Back at the Year in Research: 2019
Research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
Platinum-Based Therapy Can Significantly Improve Survival for Some Pancreatic Cancer Patients
Dr. Michael Pishvaian explains how platinum-based therapy can improve the survival of pancreatic cancer patients with a specific mutation.
Representing Genetic and Clinical Diversity in Pancreatic Cancer
Dr. Kentaro Sudo explores the possible causes for different responses to drugs among ethnic groups, pointing to the need for clinical diversity in trials.
Pancreatic Cancer Exceptional Responders and the Immune System Link
Dr. Vinod Balachandran looks at the immune system of exceptional responders–patients who respond extremely well to chemotherapy–for treatment clues.
Testing a Different Approach to Pancreatic Cancer Treatment
A drug that is epigenetic therapy, which alters how DNA behaves, is being tested in a clinical trial for pancreatic cancer.
Genetic Testing for All Pancreatic Cancer Patients
A study by Dr. Gloria Petersen’s research team has led to an official recommendation that all pancreatic cancer patients get genetic testing.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Tough Tortoise of a Drug Beating Metastatic Pancreatic Cancer
Rexahn Pharmaceuticals is testing RX-3117, a slow-releasing drug similar to gemcitabine, in a clinical trial for metastatic pancreatic cancer patients.
Investigating a Drug Used for Other Cancers
In a clinical trial, researchers are adding the drug decitabine to gemcitabine, for patients with advanced cancer that is not responding to treatment.
Most Cancer Mutations Are Random DNA Mistakes
In a large study, Dr. Bert Vogelstein of Johns Hopkins found that a majority of cancers, including pancreatic cancer, are caused by random mutations of DNA.
An Immunotherapy Game Changer
Immunotherapy with Keytruda (pembrolizumab) is approved for use in cancer patients with certain genetic defects in their tumors.
Developing a Screening Test for Pancreatic Cancer
One focus of research for Dr. Anirban Maitra is to develop a simple screening test for pancreatic cancer, to provide an earlier diagnosis of the disease.
New Biopsy Shows Promise For Pancreatic Cancer Patients
Trovagene is developing a liquid biopsy for pancreatic cancer patients, to allow doctors to test for cancer and track treatment response.